Gennao Bio Unveils Preclinical Data on GMAB ADC
Today, Gennao Bio, a private genetic medicine enterprise pioneering targeted nucleic acid therapies, revealed fresh preclinical findings regarding the use of its non-viral, cell-penetrating gene monoclonal antibody (GMAB) platform technology. These results showcase its potential as an antibody-drug conjugate (ADC)…
Genialis RNA Biomarker Predicts KRAS Outcomes in Lung Cancer
Today at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, Genialis, a leading RNA-biomarker company, unveiled their latest AI/ML classifier, Genialis™ krasID. This innovative tool accurately predicts clinical benefit in patients treated with sotorasib, a…
Ferronova Initiates Nanoparticle Trial for Gastric & Esophageal Cancers
Australian biotech firm, Ferronova, has commenced a clinical trial featuring their FerroTrace® nanoparticle technology in individuals diagnosed with gastric and esophageal cancers. This trial follows the successful completion of a first-in-human trial conducted between 2020 and 2022, focusing on oral…
Onchilles Pharma Unveils AACR 2024 Preclinical Data: Promising Treatment Potential
Onchilles Pharma, a pioneering biotech firm specializing in cancer treatments harnessing a unique innate immune approach for targeted and potent tumor eradication, revealed groundbreaking preclinical findings today. The data pertained to N17465 administered systemically, presented orally, and N17350 directed at…
Alnylam’s Positive Findings: Zilebesiran in Hypertension Study
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a prominent RNAi therapeutics firm, has unveiled encouraging outcomes from the KARDIA-2 Phase 2 trial. This study assessed the effectiveness and safety of a single subcutaneous dose of zilebesiran alongside one of three standard antihypertensive…
Edgewood Oncology: Promising BTX-A51 Study Results in Liposarcoma Preclinical Models
Edgewood Oncology, a biotech company specializing in BTX-A51 treatments for hematologic malignancies and solid tumors, has revealed fresh preclinical findings. The study, conducted by Dana-Farber Cancer Institute and Hebrew University-Hadassah Medical School, explores BTX-A51’s potential in human liposarcoma (LPS). These…
Quanta Magneto Technology™ Dominates Urological Laser World
During the 39th European Association of Urology Congress (EAU), Quanta System solidifies its position as a global leader in laser manufacturing, introducing a groundbreaking solution for stone treatment: Quanta Magneto Technology™. This innovation marks a significant advancement in urological care…
Shockwave Medical Acquisition by Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) have announced a definitive agreement for Johnson & Johnson to acquire all outstanding shares of Shockwave for $335.00 per share in cash, representing an enterprise value of approximately $13.1…
Natera’s Positive Analysis in IMvigor011 Trial for Bladder Cancer
Natera, a leader in cell-free DNA testing, presents findings from the IMvigor011 study at the EAU Congress 2024. The analysis focuses on muscle-invasive bladder cancer (MIBC) patients who tested negative with Signatera™, Natera’s molecular residual disease (MRD) test. IMvigor011, sponsored…
Nucleai’s AI Advances Cancer Diagnostics at AACR 2024
Nucleai, a leader in spatial AI biomarkers, will present pioneering advancements in cancer diagnostics at the AACR Annual Meeting. Their posters will introduce novel AI spatial biomarkers and enhanced histopathology workflows poised to transform cancer treatment. One poster, developed with…
Cardinal Health Receives Top Recognition for Supply Chain Resilience
Cardinal Health’s U.S. medical products distribution division proudly announced today that it has been honored with the HIRC Resiliency Partner Badge, achieving a prestigious Diamond-level rating for outstanding performance in supply chain resilience maturity. The HIRC’s Resiliency Badge program, recognized…
Cardinal Health Reveals OTC Pharmaceutical Distribution Center Location
Today, Cardinal Health (NYSE: CAH) announced the commencement of construction for a new 350,000 square-foot logistics center in Columbus, Ohio. This center will serve as a centralized replenishment hub for distributing over-the-counter consumer health products in support of its core…